<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05023993</url>
  </required_header>
  <id_info>
    <org_study_id>20676</org_study_id>
    <secondary_id>NCI-2021-02807</secondary_id>
    <secondary_id>20676</secondary_id>
    <secondary_id>P30CA033572</secondary_id>
    <nct_id>NCT05023993</nct_id>
  </id_info>
  <brief_title>The Effect of Exercise and Nicotinamide Riboside Muscle Health and Insulin Resistance in Survivors of Childhood Cancer</brief_title>
  <official_title>The Effect of Exercise and Nicotinamide Riboside on Muscle Health and Insulin Resistance in Adult Survivors of Childhood Cancer With Prediabetes: A Pilot Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial studies the effect of exercise and nicotinamide riboside on muscle health and&#xD;
      insulin resistance in adult survivors of childhood cancer with prediabetes (elevated blood&#xD;
      sugar level that is not high enough to be considered diabetes). Nicotinamide riboside is a&#xD;
      dietary supplement which is similar to vitamin B3. Information collected in this study may&#xD;
      help the future development of regimens to improve metabolic outcomes such as muscle health&#xD;
      and insulin resistance (when the body is not normally responding to insulin) in childhood&#xD;
      cancer survivors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. Evaluate the feasibility of conducting a home exercise and nutrition intervention in&#xD;
      childhood cancer survivors (CCS) with a history of prediabetes.&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. Describe the association between patient demographics and treatment exposures and&#xD;
      subsequent hyperglycemia and skeletal muscle health in childhood cancer survivors.&#xD;
&#xD;
      II. Describe the effect of exercise with or without nicotinamide riboside (NR) on&#xD;
      hyperglycemia and skeletal muscle health in CCS with a history of prediabetes.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 arms.&#xD;
&#xD;
      ARM I: Patients complete 18 home exercise sessions over 30 minutes each, 3 days per weeks for&#xD;
      6 weeks.&#xD;
&#xD;
      ARM II: Patients complete home exercise as in Arm I. Patients also receive nicotinamide&#xD;
      riboside orally (PO) daily for 6 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 20, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of a nutrition and exercise program in childhood cancer survivors (CCS)</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>The current protocol will be considered feasible if:&#xD;
&gt;= 50% of eligible patients that are approached for participation enroll onto the study,&#xD;
&gt;= 70% of enrolled participants successfully complete all study assessments (i.e. physical function tests, blood draw, imaging, and questionnaires at baseline and 6 weeks, and&#xD;
Enrolled participants demonstrate &gt;= 70% compliance with prescribed exercise and nicotinamide riboside.&#xD;
Feasibility measures 2 and 3 will be assessed for the entire group of 20 subjects as a whole.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hematopoietic and Lymphoid Cell Neoplasm</condition>
  <condition>Malignant Solid Neoplasm</condition>
  <condition>Prediabetes</condition>
  <arm_group>
    <arm_group_label>Arm I (home exercise)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients complete 18 home exercise sessions over 30 minutes each, 3 days per weeks for 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (home exercise, nicotinamide riboside)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients complete home exercise as in Arm I. Patients also receive nicotinamide riboside PO daily for 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exercise Intervention</intervention_name>
    <description>Complete home exercise</description>
    <arm_group_label>Arm I (home exercise)</arm_group_label>
    <arm_group_label>Arm II (home exercise, nicotinamide riboside)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nicotinamide Riboside</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm II (home exercise, nicotinamide riboside)</arm_group_label>
    <other_name>Niagen</other_name>
    <other_name>NR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  History of childhood cancer&#xD;
&#xD;
          -  History of prediabetes (HbA1c 5.7-6.4%)&#xD;
&#xD;
          -  In remission at time of enrollment&#xD;
&#xD;
          -  Time between completion of cancer-directed therapy and study entry: &gt;= 6 months&#xD;
&#xD;
          -  At least 18 years of age at time of enrollment&#xD;
&#xD;
          -  Able to access online exercise program at home&#xD;
&#xD;
          -  Ability to tolerate the prescribed resistance exercise program&#xD;
&#xD;
          -  English-speaking&#xD;
&#xD;
          -  Able to understand and sign the study specific informed consent form (ICF)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Taking a nicotinamide adenine dinucleotide (NAD)+ precursor in the two weeks prior to&#xD;
             enrollment&#xD;
&#xD;
          -  Currently taking medication for hyperglycemia or diabetes&#xD;
&#xD;
          -  Females who are pregnant or planning to become pregnant&#xD;
&#xD;
          -  Currently recovering from an injury&#xD;
&#xD;
          -  Contraindication to magnetic resonance imaging (MRI)&#xD;
&#xD;
          -  Pacemaker&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rusha Bhandari</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Rusha Bhandari</last_name>
      <phone>626-256-4673</phone>
      <phone_ext>81102</phone_ext>
      <email>rbhandari@coh.org</email>
    </contact>
    <investigator>
      <last_name>Rusha Bhandari</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 4, 2021</study_first_submitted>
  <study_first_submitted_qc>August 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

